CPMD (Cannapharmarx) Inventory-to-Revenue : 3.95 (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cannapharmarx's Average Total Inventories for the quarter that ended in Sep. 2024 was $1.23 Mil. Cannapharmarx's Revenue for the three months ended in Sep. 2024 was $0.31 Mil. Cannapharmarx's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 3.95.

Cannapharmarx's Inventory-to-Revenue for the quarter that ended in Sep. 2024 increased from Jun. 2024 (0.00) to Jun. 2024 (3.95)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cannapharmarx's Days Inventory for the three months ended in Sep. 2024 was 168.16.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cannapharmarx's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.54.

Cannapharmarx Inventory-to-Revenue Historical Data

The historical data trend for Cannapharmarx's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx Inventory-to-Revenue Chart

Cannapharmarx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

Cannapharmarx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	40.08	-	3.95

Competitive Comparison of Cannapharmarx's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannapharmarx's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's Inventory-to-Revenue falls into.

Save Embed

;

Save Embed

;

Cannapharmarx Inventory-to-Revenue Calculation

Cannapharmarx's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	1.134)	/	1 )	/	0
=	1.134					/	0
=	N/A

Cannapharmarx's Inventory-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

	Inventory-to-Revenue (Q: Sep. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2024 )	+	Total Inventories (Q: Sep. 2024 ))	/	count )	/	Revenue (Q: Sep. 2024 )
=	( (1.242	+	1.22)	/	2 )	/	0.312
=	1.231					/	0.312
=	3.95

Cannapharmarx (OTCPK:CPMD) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cannapharmarx's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	1.231	/	0.668	*	365 / 4
	=	168.16

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cannapharmarx's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	0.668	/	1.231
	=	0.54

Cannapharmarx Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannapharmarx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 3rd Street SW, Suite 3600, Calgary, AB, CAN, T2P 5C5

Website

https://www.cannapharmarx.com

Cannapharmarx Inc is involved in the cannabis sector. The company negotiates, acquires, and develops various cannabis cultivation projects throughout Canada. Its three projects include the Hanover Project; the Great Northern Project, and the Acquisition of Sunniva Medical.

Executives

Anthony Michael Panek	director	95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin	director, officer: Chief Executive Officer	C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels	officer: Chief Financial Officer	SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman	director	302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman	officer: Chief Operating Officer	1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson	director	977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick	10 percent owner	7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson	director	PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia	director, 10 percent owner	2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess	director	2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood	director	P.O. BOX 4375, DILLON CO 80435
James E Smeeding	director	4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife	director	9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule	director	C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920